On the 25th, the KOSPI index closed higher. This is interpreted as the market being influenced by the expectation of eased tariff risks amid a rise in the U.S. stock market the previous day. Foreign investors also turned to a net buying position for the first time in 11 days. The transaction volume in the securities market rose to 8 trillion won.
On this day, the KOSPI index recorded 2,546.30, up 23.97 points (0.95%) from the previous trading day. In the securities market, foreigners and institutions purchased 224.8 billion won and 498.9 billion won, respectively, while individuals sold 772.7 billion won.
In the securities market, sectors such as semiconductors, shipbuilding, finance, and machinery showed upward trends. While Samsung Electronics remained unchanged, SK hynix rose 3.42%, and HD Hyundai Heavy Industries had an increase of over 7%. KB Financial Group and Shinhan Financial Group rose by 2.72% and 2.05%, respectively, while Hanwha Ocean increased by 11%.
Lee Kyung-min, head of the investment strategy team at DAISHIN SECURITIES, noted, "The successful evaluation by the U.S. regarding the high-level 2+2 trade consultation between South Korea and the U.S. that took place the previous day, along with reports that the two countries aim to promote a transaction for mutual tariff elimination by July, has improved the overall investment sentiment."
He added, "Regarding the U.S.-China tariff negotiations, President Trump reiterated that talks with China are ongoing, which has heightened the expectation of eased tariff risks."
The KOSDAQ index closed at 729.69, up 3.61 points (0.5%) compared to the previous day. In the KOSDAQ market, foreigners were net buyers of 78.3 billion won, while individuals and institutions sold 5.3 billion won and 64.1 billion won, respectively.
In the KOSDAQ market, sectors including pharmaceuticals and biotechnology, along with high market capitalization stocks, struggled. LEENO Industrial rose 11.3% due to a stock split effect, but Alteogen fell by over 5%. Kolon TissueGene also declined by 4.32%. Additionally, LigaChem Biosciences (-1.68%), CLASSYS (-0.94%), and HUGEL (-0.28%) showed weaknesses.
Lee Jae-won, a researcher at Shinhan Investment Corporation, explained, "Alteogen reacted to the lawsuit regarding the patent infringement of Halozyme's Merck subcutaneous injection (SC), which resulted in an overall decline in investment sentiment for the pharmaceutical and biotechnology sectors, limiting the index's upper bound."